Suppr超能文献

[奈多罗米钠(替乐喘)治疗儿童重症哮喘]

[Sodium nedocromil (Tilade) in the treatment of severe forms of asthma in children].

作者信息

Petrů V, Carbolová A, Matulka M, Stejskal J

机构信息

I. dĕtská klinika, 2. lékarské fakulty, Univerzity Karlovy, Praha.

出版信息

Cesk Pediatr. 1991 Jul;46(6-7):349-51.

PMID:1659952
Abstract

Twenty-four children with medium severe and severe asthma were treated for a period of three months with sodium nedocromil (Tilade), twice a day 4 mg in a dispensed aerosol. All patients took concurrently on a long-term basis various antiasthmatic drugs and half the children also corticosteroids. Evaluation of the effect was based on changes of the clinical picture, drug consumption and some other examinations. The authors compared the state one month before onset of treatment with the last month during the three-month therapy and one month after termination of therapy. In the entire group of patients gradually the number of asthmatic attacks declined, the greatest decline was observed during the third month of treatment. At the same time a statistically significant improvement of symptoms was recorded characterizing the clinical condition of the patients during day and night. Both these parameters deteriorated again one month after termination of treatment. The consumption of aerosol sympathomimetics and partly also of theophylline declined. Corticotherapy was not affected and pulmonary functions did not improve. The investigated immunological parameters did not change. With the exception of two patients where inhalation had an irritating effect, treatment was tolerated well and produced no side-effects. Sodium nedocromil is a drug which extends the spectrum of preventive antiasthmatics, but has no major effect on children with the most severe forms of asthma.

摘要

24名中度至重度哮喘患儿接受了奈多罗米钠(替乐)治疗,为期3个月,每天两次,通过定量气雾剂给药4毫克。所有患者同时长期服用各种抗哮喘药物,半数患儿还服用皮质类固醇。疗效评估基于临床表现、药物使用情况及其他一些检查的变化。作者比较了治疗开始前1个月、3个月治疗期间最后1个月以及治疗结束后1个月的情况。在整个患者组中,哮喘发作次数逐渐减少,治疗第3个月时减少最为明显。与此同时,白天和夜间患者临床症状有统计学意义的显著改善。治疗结束1个月后,这两个参数又恶化了。气雾剂拟交感神经药以及部分茶碱的使用量减少。皮质激素治疗未受影响,肺功能未改善。所研究的免疫参数未改变。除两名患者吸入时有刺激作用外,治疗耐受性良好,未产生副作用。奈多罗米钠是一种可扩大预防性抗哮喘药物范围的药物,但对最严重形式的哮喘患儿无重大影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验